Bookmark and Share
SR-03000002555 (CID 53362017) - Compound BioActivity Data
.
BioActivity Outcomes:
Probe(8)
 
 
Inactive(5)
 
 
Top Targets:
Lactamase B(11)
 
 
 
PRK15442(1)
 
 
ampC(1)
 
 
BioAssay Types:
Confirmatory(6)
 
 
 
BioActivity Types:
IC50(4)
 
 
 
Ki(2)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 12    Data Row: 13   Total Pages: 1   
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID134220672]
Ki 0.183Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624083, Type: confirmatory]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
2
[SID134220672]
MIC [4 fold reduction] 0.391Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
3
[SID125264855]
IC50 0.5481Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624079, Type: confirmatory]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
4
[SID125264855]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]metallo-beta-lactamase IMP-1 [Pseudomonas aeruginosa] [gi:27368096]
View
5
[SID125264855]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
6
[SID134220672]
Ki 0.93Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1 [AID624084, Type: confirmatory]metallo-beta-lactamase IMP-1 [Pseudomonas aeruginosa] [gi:27368096]
View
7
[SID125264855]
IC50 3.018Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1 [AID624085, Type: confirmatory]metallo-beta-lactamase IMP-1 [Pseudomonas aeruginosa] [gi:27368096]
View
8
[SID125264855]
MIC [4 fold reduction] 3.125Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): VIM-2-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624081, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
9
[SID125264855]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other]NDM-1 metallo-beta-lactamase [Escherichia coli] [gi:345105285]
View
10
[SID125264855]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant IMP-1 transformed P. aeruginosa (KN20) in the presence of imipenem (synergy) [AID624095, Type: other]metallo-beta-lactamase IMP-1 [Pseudomonas aeruginosa] [gi:27368096]
View
11
[SID125264855]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2 transformed P. aeruginosa (PA641) in the presence of imipenem (synergy) [AID624080, Type: other]metallo beta-lactamase [Pseudomonas aeruginosa] [gi:7381449]
View
12
[SID125264855]
IC50 60Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit AmpC [AID624090, Type: confirmatory]beta-lactamase [Escherichia coli] [gi:37718709]
View
13
[SID125264855]
IC50 60Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit TEM-1 [AID624092, Type: confirmatory]Beta lactamase [Pseudomonas aeruginosa] [gi:114881106]
View